Company: ARWR
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001628280-25-038858
Chunk: 48

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 48
---
,000 202740,000 202815,000 202915,000 Thereafter216,503 Total$326,503 In May 2025, Visirna entered into the Revolving Credit Agreement with Bank of Zhejiang. The maximum aggregate credit facility is 73.0 million Chinese Yuan ($10.0 million) bearing an annual interest rate of 4.1%. The term of each loan is twelve months. The amount outstanding as of June 30, 2025 was 50.8 million Chinese Yuan ($7.1 million) on the credit facility which was classified as other current liabilities.

24

NOTE 13. NET (LOSS) INCOME PER SHARE

The following table presents the computation of basic and diluted net (loss) income per share for the three and nine months ended June 30, 2025 and 2024.                            Three Months Ended June 30,Nine Months Ended June 30,2025202420252024(in thousands, except per share amounts)Numerator:Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.$(175,241)$(170,793)$22,119 $(428,957)Denominator:Weighted-average basic shares outstanding (1)139,039 124,199 132,385 118,260 Effect of dilutive securities— — 967 — Weighted-average diluted shares outstanding (1)139,039 124,199 133,352 118,260 Basic net (loss) income per share$(1.26)$(1.38)$0.17 $(3.63)Diluted net (loss) income per share$(1.26)$(1.38)$0.17 $(3.63)(1) Includes shares of common stock into which the Avoro Pre-Funded Warrants may be exercised. See Note 6.The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net (loss) income per share because to include them would be anti-dilutive.Three Months Ended June 30,Nine Months Ended June 30,2025202420252024(in thousands)Options768 753 756 711 Restricted stock units5,178 3,976 4,770 4,060 Total5,946 4,729 5,526 4,771 

NOTE 14. INCOME TAXES

The